BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 25048845)

  • 1. Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients.
    Lúcia M; Crespo E; Melilli E; Cruzado JM; Luque S; Llaudó I; Niubó J; Torras J; Fernandez N; Grinyó JM; Bestard O
    Clin Infect Dis; 2014 Dec; 59(11):1537-45. PubMed ID: 25048845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.
    Abate D; Saldan A; Mengoli C; Fiscon M; Silvestre C; Fallico L; Peracchi M; Furian L; Cusinato R; Bonfante L; Rossi B; Marchini F; Sgarabotto D; Rigotti P; Palù G
    J Clin Microbiol; 2013 Aug; 51(8):2501-7. PubMed ID: 23678073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
    J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
    BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor.
    Schachtner T; Stein M; Reinke P
    Transplantation; 2017 Oct; 101(10):e315-e325. PubMed ID: 28594749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation.
    Bestard O; Lucia M; Crespo E; Van Liempt B; Palacio D; Melilli E; Torras J; Llaudó I; Cerezo G; Taco O; Gil-Vernet S; Grinyó JM; Cruzado JM
    Am J Transplant; 2013 Jul; 13(7):1793-805. PubMed ID: 23711167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study.
    Chanouzas D; Small A; Borrows R; Ball S
    PLoS One; 2018; 13(3):e0193968. PubMed ID: 29558479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience.
    Favi E; Santangelo R; Iesari S; Morandi M; Marcovecchio GE; Trecarichi EM; Salerno MP; Ferraresso M; Citterio F; Romagnoli J
    Transplant Proc; 2017 Oct; 49(8):1766-1772. PubMed ID: 28923622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
    Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients.
    Egli A; Binet I; Binggeli S; Jäger C; Dumoulin A; Schaub S; Steiger J; Sester U; Sester M; Hirsch HH
    J Transl Med; 2008 Jun; 6():29. PubMed ID: 18541023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of Cytomegalovirus-Specific Cytokine Production after Modulation of the Costimulation in Kidney Transplant Patients.
    Dornieden T; Wilde B; Korth J; Werner K; Horn PA; Witzke O; Lindemann M
    J Immunol Res; 2019; 2019():3926175. PubMed ID: 30931336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.
    Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P
    Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic of the CMV-specific T-cell immune response and CMV infection in CMV-seropositive kidney transplant recipients receiving rabbit anti-thymocyte globulin induction therapy: A pilot study.
    Martín-Gandul C; Pérez-Romero P; Mena-Romo D; Molina-Ortega A; González-Roncero FM; Suñer M; Bernal G; Cordero E;
    Transpl Infect Dis; 2018 Jun; 20(3):e12883. PubMed ID: 29570917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic usefulness of the cytomegalovirus (CMV)-specific T cell-based assay for predicting CMV infection after kidney transplant.
    Kim T; Lee HJ; Kim SM; Jung JH; Shin S; Kim YH; Sung H; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
    Korean J Intern Med; 2020 Mar; 35(2):438-448. PubMed ID: 29865778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection.
    Abate D; Fiscon M; Saldan A; Cofano S; Mengoli C; Sgarabotto D; d'Agostino C; Barzon L; Cusinato R; Toscano G; Feltrin G; Gambino A; Gerosa G; Palù G
    J Clin Microbiol; 2012 Jun; 50(6):1974-80. PubMed ID: 22461674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
    Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
    Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CMV-specific Cell-mediated Immunity at 3-month Prophylaxis Withdrawal Discriminates D+/R+ Kidney Transplants at Risk of Late-onset CMV Infection Regardless the Type of Induction Therapy.
    Jarque M; Melilli E; Crespo E; Manonelles A; Montero N; Torras J; Cruzado JM; Luque S; Gil-Vernet S; Grinyó JM; Bestard O
    Transplantation; 2018 Nov; 102(11):e472-e480. PubMed ID: 30130330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary Cytomegalovirus Infection Significantly Impacts Circulating T Cells in Kidney Transplant Recipients.
    Meijers RW; Litjens NH; Hesselink DA; Langerak AW; Baan CC; Betjes MG
    Am J Transplant; 2015 Dec; 15(12):3143-56. PubMed ID: 26211927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant.
    López-Oliva MO; Martinez V; Buitrago A; Jiménez C; Rivas B; Escuin F; Santana MJ; Selgas R; Bellón T
    Transplantation; 2014 Apr; 97(8):839-45. PubMed ID: 24345896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients.
    Rittà M; Costa C; Sidoti F; Ballocco C; Ranghino A; Messina M; Biancone L; Cavallo R
    New Microbiol; 2015 Jul; 38(3):329-35. PubMed ID: 26147141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.